Search

Your search keyword '"B. Massuti"' showing total 379 results
Start Over Author "B. Massuti"
379 results on '"B. Massuti"'

1. 12P Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)

Author

Peressini, M., primary, Cubells, C. Martí, additional, Calderon, V. Gutierrez, additional, Sureda, B. Massuti, additional, Majem, M., additional, García-Campelo, M.R., additional, Tain, P. Diz, additional, Isla Casado, M.D., additional, Paul, A. Moreno, additional, Navalon, F.J. Garcia, additional, Molero, M., additional, Adradas, V., additional, Gallego, E. Conde, additional, Paz-Ares, L., additional, and Zugazagoitia, J., additional

Published
2023
Full Text
View/download PDF

2. 72P Correlation of serum cytokine patterns and clinicopathological factors in breast carcinoma patients

Author

Montoyo-Pujol, Y.G., primary, Martínez-Peinado, P., additional, Pascual-García, S., additional, López-Jaén, A.B., additional, Ponce, J., additional, Cubo, I. Lozano, additional, Sureda, B. Massuti, additional, Castellón-Molla, E., additional, Delgado, S., additional, Martín-Bayón, T.A., additional, Ballester, H., additional, Ramos, A., additional, Sempere-Ortells, J.M., additional, and Peiro-Cabrera, G., additional

Published
2023
Full Text
View/download PDF

3. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations

Author

R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho, Pulmonary medicine, and CCA - Cancer Treatment and quality of life

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Population, Phases of clinical research, bevacizumab, NSCLC, law.invention, T790M, Randomized controlled trial, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Osimertinib, education, Protein Kinase Inhibitors, education.field_of_study, Acrylamides, Aniline Compounds, business.industry, Standard treatment, Hematology, EGFR mutations, ErbB Receptors, osimertinib, Mutation, business, randomised controlled trial, medicine.drug
Abstract

Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M mutations, progression inevitably occurs. The angiogenic pathway is implicated in EGFR TKI resistance. Patients and methods: BOOSTER is an open-label randomised phase II trial investigating the efficacy and safety of combined osimertinib 80 mg daily and bevacizumab 15 mg/kg every 3 weeks, versus osimertinib alone, in patients with EGFR-mutant advanced NSCLC and acquired T790M mutations after failure on previous EGFR TKI therapy. Primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR) and adverse events (AEs). Results: Between May 2017 and February 2019, 155 patients were randomised (combination: 78; osimertinib: 77). At data cut-off of 22 February 2021, median follow-up was 33.8 months [interquartile range (IQR): 26.5-37.6 months] and 129 (83.2%) PFS events were reported in the intention-to-treat population. There was no difference in median PFS between the combination [15.4 months; 95% confidence interval (CI) 9.2-18.0 months] and osimertinib arm (12.3 months; 95% CI 6.2-17.2 months; stratified log-rank P = 0.83), [hazard ratio (HR) = 0.96; 95% CI 0.68-1.37]. Median OS was 24.0 months (95% CI 17.8- 32.1 months) in the combination arm and 24.3 months (95% CI 16.9-37.0 months) in the osimertinib arm (stratified log-rank P = 0.91), (HR = 1.03; 95% CI 0.67-1.56). Exploratory analysis revealed a significant interaction of smoking history with treatment for PFS (adjusted P = 0.0052) with a HR of 0.52 (95% CI 0.30-0.90) for smokers, and 1.47 (95% CI 0.92-2.33) for never smokers. ORR was 55% in both arms and the median time to treatment failure was significantly shorter in the combination than in the osimertinib arm, 8.2 months versus 10.8 months, respectively (P = 0.0074). Safety of osimertinib and bevacizumab was consistent with previous reports with grade >= 3 treatment-related AEs (TRAEs) reported in 47% and 18% of patients on combination and osimertinib alone, respectively. Conclusions: No difference in PFS was observed between osimertinib plus bevacizumab and osimertinib alone. Grade >= 3 TRAEs were more common in patients on combination.

Published
2022

4. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

Author

B. Sierra-Rodero, C. Martínez-Toledo, M. Molina-Alejandre, V. Calvo, E. Nadal, B. Massuti Sureda, R. García Campelo, C. Gonzalez Ojea, A. Martinez-Marti, M. Domine Gomez, S. Ponce Aix, M.A. Insa Molla, J. De Castro Carpeno, M. Majem, I.C. Barneto Aranda, D. Rodriguez-Abreu, E. del Barco, M. Cobo Dols, M. Provencio Pulla, and A. Cruz-Bermudez

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2023

5. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

Casarrubios, M., primary, Cruz-Bermudez, A., additional, Sierra-Rodero, B., additional, Martinez, C., additional, Nadal, E., additional, Insa Molla, M.A., additional, Martinez, J. Mosquera, additional, Ojea, C. Gonzalez, additional, Gomez, M. Domine, additional, Tarruella, M. Majem, additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro Carpeno, J., additional, Dols, M. Cobo, additional, Vivanco, G. Lopez, additional, Caro, R. Bernabe, additional, Segarra, N. Vinolas, additional, Aranda, I.C. Barneto, additional, Sureda, B. Massuti, additional, and Pulla, M. Provencio, additional

Published
2022
Full Text
View/download PDF

8. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

Author

S. Hernandez, J.L. Rodriguez Carrillo, A. Caminoa, A. Benito, R. Martinez, M. Alonso, S. Clave, E. Arriola, I. Esteban-Rodriguez, J. De Castro, I. Sansano, E. Felip, I. Abdulkader, J. Garcia, F. Rojo, M. Domine, C. Teixido, N. Reguart, D. Compañ, A. Insa, N. Mancheño, S. Palanca, O. Juan, N. Baixeras, E. Nadal, M. Cebollero, A. Calles, P. Martin, C. Salas, M. Provencio, I. Aranda, B. Massuti, L. Lopez-Vilaro, M. Majem, P. Garrido, L. Paz-Ares, F. Lopez-Rios, and E. Conde

Subjects
Pulmonary and Respiratory Medicine, Oncology
Published
2022

9. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, C. Martinez, E. Nadal, M.A. Insa Molla, J. Mosquera Martinez, C. Gonzalez Ojea, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, R. Bernabe Caro, N. Vinolas Segarra, I.C. Barneto Aranda, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

10. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain

Author

M.R. Garcia Campelo, M. Domine Gomez, J. De Castro Carpeno, A.L. Moreno Vega, S. Ponce Aix, E. Arriola, E. Carcereny Costa, M. Majem Tarruella, G. Huidobro Vence, E. Esteban Gonzalez, J. Fuentes Pradera, A.L.O. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, L. Vila Martinez, A. Blasco Cordellat, C.A. Fajardo, L. Crama, N. Lerones Laborda, and M. Cobo Dols

Subjects
Oncology, Hematology
Published
2022

11. 382P Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study

Author

M. Valladares, M.J. Safont Aguileria, E. González-Flores, P. García Alfonso, A.M. López Muñoz, E. Aranda Aguilar, E. Falco Ferrer, N. Rodriguez-Salas, L. Cirera, M. Llanos-Munoz, J. Aparicio, P. Pimentel, A.O. Castillo Trujillo, M. Salgado Fernandez, M.A. Salud Salvia, R. Vidal Tocino, B. Massuti Sureda, R. Garcia-Carbonero, M.A.D.L.A. Vicente Conesa, and A. Lloansi Vila

Subjects
Oncology, Hematology
Published
2022

13. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Author

Franco, F.F., primary, Carcereny, E., additional, Castro, R. Lopez, additional, Rodriguez, D., additional, Dols, M.A. Cobo, additional, Caro, R. Bernabe, additional, Cordellat, A. Blasco, additional, Sureda, B. Massuti, additional, Granados, A.L. Ortega, additional, Barco, E. del, additional, Bosch-Barrera, J., additional, Guirado, M., additional, Gonzalez-Larriba, J.L., additional, Vidal, O. Juan, additional, Martinez, J. Mosquera, additional, Rodriguez, J.M. Oramas, additional, Gonzalez, M.A. Sala, additional, Calvo, V., additional, Gonzalez, A. Estival, additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

14. 1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer

Author

Calvo, V., primary, Niazmand, E., additional, Carcereny, E., additional, Jozashoori, S., additional, Rodriguez, D., additional, Castro, R. Lopez, additional, Guirado, M., additional, Camps, C.J., additional, Caro, R. Bernabe, additional, Granados, A.L. Ortega, additional, Sureda, B. Massuti, additional, Dols, M.A. Cobo, additional, Campelo, M.R. Garcia, additional, Barco, E. del, additional, Bosch-Barrera, J., additional, Gonzalez-Larriba, J.L., additional, Moran, T., additional, Collazo, A., additional, Vidal, M.E., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

15. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Author

J.L. González Larriba, R. Bernabé, B. Massuti, D. Rodriguez Abreu, R. López-Castro, J. Mosquera, M. Cucurull, Manuel Domine, Ana Ortega, Oscar Juan, M. Provencio, M. Cobo, A. Collazo-Lorduy, V. Calvo, M. Guirado, Enric Carcereny, M. Martínez-Cutillas, E. Del Barco, Carlos Camps, J. Bosch Barrera, Gustavo Benítez, and C. Gonzalez Ojeda

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, biology, business.industry, Cancer, medicine.disease, Transthyretin, Internal medicine, biology.protein, Medicine, Family history, business, Lung cancer
Published
2021

16. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

Author

R. Laza Briviesca, Maria Rosario Garcia Campelo, Delvys Rodriguez Abreu, Margarita Majem, Roberto Serna, A. Insa, Manuel Domine, Guillermo López Vivanco, Ana Royuela, V. Calvo, B. Massuti, C. Benito, Isidoro Barneto, E. Pereira, R. Bernabé, Amândio Cruz, Estela Sánchez-Herrero, E. Del Barco, M. Casarrubios, Alex Martinez-Marti, E. Nadal, M. Cobo, M. Provencio, Nuria Viñolas, Amalia Pérez Romero, J. de Castro, and Santiago Viteri

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Multivariate analysis, business.industry, medicine.disease, Clinical trial, Chemoimmunotherapy, Internal medicine, Stage IIIA NSCLC, Long term survival, medicine, Nivolumab, Lung cancer, business, Chemo immunotherapy
Abstract

Introduction: There are currently no predictive biomarkers for long-term survival after neoadjuvant chemoimmunotherapy. However, the identification of non-small lung cancer (NSCLC) patients who obtain long-term benefit from chemoimmunotherapy is essential to optimize therapies. Methods: Using samples from NADIM clinical trial (NCT03081689), in which resectable stage IIIA NSCLC patients were treated with neoadjuvant chemo-immunotherapy with nivolumab, we have evaluated the capacity of ctDNA levels before treatment initiation to predict overall survival (OS) and progression-free survival (PFS) by calculating Harrell’s C-statistic and we compare its predictive value with classical survival surrogates as the pathological response and clinical response assessed according to RECIST criteria v.1.1. The ctDNA was analyzed by NGS, using the Oncomine Pan-Cancer Cell-Free Assay™ (Thermo Fisher Scientific®). To explore the prognostic value of the amount of ctDNA at baseline, for each positive plasma sample, we calculated the sum of the mutant allele frequency (MAF) for all detected mutations. Patients who died from COVID19 were excluded from this analysis. Results: In our study, clinical responses based on RECIST criteria were not predictive for OS or PFS. On the contrary, in the multivariate analysis, patients with low ctDNA levels (

Published
2021

17. 1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer

Author

M.R. Garcia Campelo, Jose-Luis Gonzalez-Larriba, V. Calvo, R. Lopez Castro, M. Cobo Dols, Carlos Camps, Thomas M. Moran, B. Massuti Sureda, E. Del Barco, M. Provencio, R. Bernabe Caro, Joaquim Bosch-Barrera, Ana Collazo, Dolors Rodríguez, Enric Carcereny, M. Guirado, A.L. Ortega Granados, S. Jozashoori, E. Niazmand, and M.E. Vidal

Subjects
Oncology, 0303 health sciences, medicine.medical_specialty, business.industry, Cancer, Hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Family history, Lung cancer, business, 030304 developmental biology
Published
2021
Full Text
View/download PDF

18. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study

Author

M. Guirado, H. Arasanz, Carlos Aguado, M. Provencio, E. Del Barco, J. Coves, Ana Laura Ortega Granados, Guillermo López Vivanco, Delvys Rodriguez-Abreu, M. Cobo, B. Massuti, A. C. Lorduy, Sergio Vazquez-Estevez, C. Lucia, Anna Estival, G. M. Serrano, Margarita Majem, B. J. Munarriz, and O. Juan-Vidal

Subjects
Cancer Research, Coronavirus disease 2019 (COVID-19), biology, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunological memory, medicine.disease, Virology, Virus, Reverse transcription polymerase chain reaction, Oncology, biology.protein, Medicine, Seroprevalence, Antibody, business, Lung cancer
Abstract

8531 Background: Coronavirus disease 2019 (COVID-19) is diagnosed by detecting the virus by reverse transcription polymerase chain reaction (RT-PCR). The majority of p go on to develop antibodies (Ab) against viral proteins. However, it is not known how long these antibodies last nor whether cancer treatments could affect the duration of immune response. The prognosis and greater or lesser vulnerability of the oncological population are also unknown. Methods: This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 was carried out in 50 Spanish hospitals. Eligibility criteria was a diagnosis of any thoracic cancer. The first determinations were performed between April 21, 2020 and June 3, 2020, either for p in follow up or in active treatment. Between September 10, 2020, and November 20, 2020, the second antibody (Ab) determination was performed in all previously seropositive p. Clinical and treatment data were collected, as was their clinical situation at study end. Study objectives were to prospectively determine seroprevalence in unselected lung cancer p during the first wave of the pandemic; the natural history of these p; the persistence of immunity more than 4 months after first determination; protection or lack thereof against reinfection after this period, and the nature of such protection; and the influence of treatments on maintenance or loss of immunity. Results: Of 1,500 p studied, 128 were seropositive, representing an overall prevalence of 8.5% seropositivity [95% confidence interval [CI], 7.2%, 10.1%]. Seventy-five percent were in active cancer treatment. COVID-19 infection was suspected in 47.7% [95% CI, 38.8%, 56.6%]. A second determination was performed on average 4.5 months later [IQR: 4; 5] and obtained for 104 of the initially seropositive p (81%). A second determination could not be obtained in 24 p, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% (32/104) of p. The severity of the infection, the need for hospitalization (p: 0.032) and the presence of symptoms at diagnosis (p: 0.02), including fever (p: 0.005) and nasal congestion (p: 0.005), were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Ab loss. At time of last follow-up among those p for whom a second determination was performed, 89% (93 p) had completely recovered from the virus, with no lasting after effects. Only 1 of the 128 (0.78%) seropositive p had died from COVID-19. Conclusions: The prevalence of infection in lung cancer p is similar to that of the general population. Immunity against SARS-CoV-2 does not appear to be compromised by treatment, persisting beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population.

Published
2021

19. 1995P Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study

Author

García-Campelo, M.R., Dómine, M., de Castro Carpeño, J., Moreno Vega, A.L., Aix, S. Ponce, Arriola, E., Carcereny, E., Majem, M., Vence, G. Huidobro, Gonzalez, E. Esteban, Pradera, J. Fuentes, Ortega Granados, A.L.O., Morales, M. Guillot, Sureda, B. Massuti, Barragan, P. Lianes, Calderon, R. Alonso, Fajardo, C.A., Crama, L., Laborda, N. Lerones, and Dols, M. Cobo

Published
2023
Full Text
View/download PDF

20. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain

Author

Nadal, E., Fernandez, C. Alvarez, Arasanz, H., Muñoz, S. Peralta, Quintela, M. Lázaro, Teixido, C., Calvo de Juan, V., Alvarez, R.M., Espinar, J. Baena, Valdivia-Bautista, J., Arriola, E., Lastra, R., Caro, R. Bernabe, Camacho, C., Cordellat, A. Blasco, Sureda, B. Massuti, Guillaumes, M. Campayo, Dols, M. Cobo, Manrique, T. Garcia, and Marquez, G.J.

Published
2023
Full Text
View/download PDF

21. 39P Determination of essential biomarkers in lung cancer: A real-world data study in Spain

Author

V. Calvo de Juan, M. Cobo Dols, D. Rodriguez-Abreu, E. Carcereny, A. Cantero, R. Bernabé Caro, G. Benitez Lopez, R. Lopez Castro, B. Massuti Sureda, E. del Barco, M.R. Garcia Campelo, M. Guirado, C.J.C. Camps Herrero, A.L.O. Ortega Granados, J.L. Gonzalez-Larriba, A. Sanchez Hernandez, C. Gonzalez Ojea, M.A. Sala Gonzalez, O.J. Juan Vidal, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

22. 53P Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Author

E. Carcereny Costa, A. Collazo Lorduy, M. Cobo Dols, D. Rodriguez Abreu, R. Bernabé Caro, R. Lopez Castro, B. Massuti Sureda, E. del Barco, M. Guirado, J. Bosch-Barrera, J.L. Gonzalez-Larriba, A. Sanchez Hernandez, O.J. Juan Vidal, J.M. Oramas Rodriguez, J. Mosquera Martinez, A.L.O. Ortega Granados, A. Padilla, M.T. Moran Bueno, A. Cantero, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

23. 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, E. Nadal, M.A. Insa Molla, M.R. Garcia Campelo, C. Garcia Benito, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez-Abreu, A. Martinez, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, N. Vinolas Segarra, I.C. Barneto Aranda, S. Viteri, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

24. 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial

Author

Postel-Vinay, S., primary, Planchard, D., additional, Antigny, M., additional, Sarto, J. Coves, additional, Gomez, M. Domine, additional, de las Penas Bataller, R., additional, Gonzalez, M.A. Sala, additional, Viteri, S., additional, Pérez, J. Pozas, additional, Texier, M., additional, Granados, A.L. Ortega, additional, Bueno, M.T. Moran, additional, Camps, C.J., additional, Lopez-Martin, A., additional, Provencio, M., additional, Gazzah, A., additional, Soria, J-C., additional, Besse, B., additional, Sureda, B. Massuti, additional, and Rosell, R., additional

Published
2021
Full Text
View/download PDF

25. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

Author

Sierra-Rodero, B., primary, Garitaonaindia, Y., additional, Martinez-Cutillas, M., additional, Nadal, E., additional, Insa, A., additional, Campelo, M.R. Garcia, additional, Rubio, J. Casal, additional, Gomez, M. Domine, additional, Tarruella, M. Majem, additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro Carpeno, J., additional, del Barco, E., additional, Viñolas, N., additional, Aranda, I.C. Barneto, additional, Sureda, B. Massuti, additional, Casarrubios, M., additional, Laza-Briviesca, R., additional, Cruz-Bermudez, A., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

26. P84.14 Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling

Author

Sandra Sanz-Moreno, M. Domine Gomez, Dietmar Fernández‐Orth, Magdalena Arnal, B. Massuti, Vadym Ivanchuk, Silvia Calabuig Fariñas, Virginia Calvo, Estela Sánchez-Herrero, R. Garcia Campelo, Roberto Serna-Blasco, M. Provencio, Noemí Reguart, Víctor González‐Rumayor, Amalia Pérez Romero, Eloisa Jantus-Lewintre, Juana Sánchez, and Carlos Camps

Subjects
Pulmonary and Respiratory Medicine, Profiling (computer programming), Oncology, business.industry, Medicine, Identification (biology), Computational biology, Liquid biopsy, business, DNA sequencing
Published
2021

27. P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer

Author

M. Cobo, N. Liu, R. Tiedt, V. Minotti, J. Vazquez, Brett G.M. Hughes, Alessandra Bearz, Michael Boyer, Denis Moro-Sibilot, Enriqueta Felip, X. Le, Michael Mark, L. Hao, Ying Cheng, B. Massuti, Juergen Wolf, and Daniel Shao Weng Tan

Subjects
Pulmonary and Respiratory Medicine, Capmatinib, Oncology, business.industry, Cancer research, Wild type, Medicine, Non small cell, Nivolumab, business, Lung cancer, medicine.disease
Published
2021

28. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients

Author

Belén Sierra-Rodero, B. Massuti, E. Del Barco, G. Lopez Vivanco, Santiago Viteri, M. Casarrubios, G. Huidobro, M.R. Garcia Campelo, Isidoro Barneto, E. Nadal, Margarita Majem, R. Laza Briviesca, A. Insa, Nuria Viñolas, Alberto Cruz-Bermúdez, J. De Castro Campeño, M. Domine Gomez, R. Bernabe Caro, Alex Martinez-Marti, M. Provencio, Delvys Rodriguez-Abreu, and M. Cobo Dols

Subjects
Pulmonary and Respiratory Medicine, Oncology, Clinical trial, medicine.medical_specialty, Immune system, business.industry, Internal medicine, medicine, Pathological response, business
Published
2021

29. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial

Author

Santiago Viteri, G. López Vivanco, M. Jove, J. Casal, M. Majem Tarruella, R. Bernabe Caro, Alex Martinez-Marti, Belén Sierra-Rodero, R. Laza Briviesca, Nuria Viñolas, J. De Castro Campeño, Alberto Cruz-Bermúdez, A. Insa, M. Casarrubios, M.R. Garcia Campelo, M. Provencio, F. Franco, M. Cobo Dols, B. Massuti, Manuel Domine, E. Del Barco, Ernest Nadal, Delvys Rodriguez-Abreu, and Isidoro Barneto

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Chemoimmunotherapy, Internal medicine, medicine, Pathological response, Tcr repertoire, business
Published
2021

30. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)

Author

Sierra-Rodero, B., Martínez-Toledo, C., Molina-Alejandre, M., Calvo, V., Nadal, E., Sureda, B. Massuti, Campelo, R. García, Ojea, C. Gonzalez, Martinez-Marti, A., Gomez, M. Domine, Aix, S. Ponce, Molla, M.A. Insa, De Castro Carpeno, J., Majem, M., Aranda, I.C. Barneto, Rodriguez-Abreu, D., del Barco, E., Dols, M. Cobo, Pulla, M. Provencio, and Cruz-Bermudez, A.

Published
2023
Full Text
View/download PDF

31. OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases

Author

Jordi Bruna, E. Pereira, Ernest Nadal, J. Mosquera, Enriqueta Felip, R. Lopez Castro, Ana Blasco, A. Estival, I. Sullivan, V. Navarro, M. Guirado, B. Massuti, Marta Simó, and G. Huidobro

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, Atezolizumab, medicine.medical_treatment, Internal medicine, medicine, Phases of clinical research, Stage iv, business
Published
2021

32. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

Author

Alejandra Caminoa, M. Provencio, Nuria Baixeras, D. Compañ, Ihab Abdulkader, Cristina Teixidó, Isidoro Barneto Aranda, E. Felip, J. de Castro, B. Massuti, Esther Conde, M. V. Alonso, Paloma Martín, L. Lopez-Vilaro, Edurne Arriola, Oscar Juan, Fernando Lopez-Rios, A. Insa, Manuel Domine, Valentina Boni, Sergi Clavé, Irene Sansano, Luis Paz-Ares, Pilar Garrido, Alipio G. Calles, José Ignacio Uribe García, M. Cebollero, Jordi Remon, Noemí Reguart, Amparo Benito, Isabel Esteban, Ernest Nadal, Belén Jiménez, A.B. Enguita, Federico Rojo, S. Hernandez, Lara Pijuan, S. Palanca, Rebeca Martinez, Margarita Majem, N. Mancheño, and Clara Salas

Subjects
Pulmonary and Respiratory Medicine, Lung, medicine.anatomical_structure, Oncology, business.industry, Cancer research, medicine, Carcinoma, Non small cell, RET Fusion, medicine.disease, business
Published
2021

33. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

Author

M. Casarrubios, Edwin R. Parra, Clara Salas, E. Pereira, I. I. Wistuba, Virginia Calvo, M. Provencio, A. Insa, R. Laza Briviesca, R. Bernabé, J. de Castro, E. Del Barco, E. Nadal, Santiago Viteri, Ana Royuela, Alex Martinez-Marti, Guillermo López Vivanco, Nuria Viñolas, Amalia Pérez Romero, M. Cobo, D. Pereiro, Amândio Cruz, Isidoro Barneto, Manuel Domine, B. Massuti, Delvys Rodriguez Abreu, Margarita Majem, and Maria Rosario Garcia Campelo

Subjects
Pulmonary and Respiratory Medicine, education.field_of_study, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Population, Gastroenterology, Carboplatin, chemistry.chemical_compound, Oncology, chemistry, Paclitaxel, Chemoimmunotherapy, Internal medicine, medicine, Adjuvant therapy, Nivolumab, education, business, Adjuvant
Abstract

Introduction: Neoadjuvant chemoimmunotherapy been shown to be highly effective in resectable stage IIIA NSCLC. Now we provide long term survival data Methods: This was an open-label, multicentre, single-arm phase 2 trial in which patients with histologically or cytologically documented stage IIIA NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 and who were deemed locally to be surgically resectable by a multidisciplinary clinical team were treated with neoadjuvant intravenous paclitaxel (200 mg/m2) and carboplatin (area under curve 6;6 mg/mL per min) plus nivolumab (360 mg) on day 1 of each 21-day cycle, for three cycles before surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 months, followed by 480 mg every 4 weeks for 8 months). Here we report progression-free survival (PFS) and Overall survival (OS) at 36 and 42 months, assessed in the modified intention-to-treat population (ITT), which included all patients who received neoadjuvant treatment, and in the per-protocol population (PP), which included all patients who had tumour resection and received at least one cycle of adjuvant treatment. Results: Median follow-up time was 37.9 months (95%CI: 36.7-40.7), with a 94% maturity at 36 months. Among the ITT population (N=46), 37 patients, constituting the PP population, received subsequent adjuvant therapy. Of them, 27 (58.7%) patients completed the adjuvant treatment (16 cycles), 10 (21.7%) patients received between 3 and 15 cycles of adjuvant therapy, and 9 (19.6%) patients did not receive adjuvant therapy. At the time of data cutoff (March 2021), progression disease was diagnosed in 14 patients and 9 deaths were recorded in the ITT population. Of these, three deaths corresponded to patients who did not undergo surgery and had disease progression, four deaths corresponded to patients who underwent surgery and had disease progression, and the two remaining deaths corresponded to patients who were diagnosed as being disease free but died from COVID19 infection. Notably, among patients who could not undergo surgery (N=5), one of them is still alive and with no evidence of disease. PFS at 36 and 42 months in the ITT population were 69.6% (95%CI: 54.1-80.7), in both cases. Similarly, PFS at 36 and 42 in the PP population were 81.1% (95%CI: 64.4-90.5) in both cases. The percentage of patients who were alive at 36 and 42 months in the modified ITT population were 81.86% (95% CI: 66.8-90.6) and 78.94% (95%CI: 63.1-88.6), respectively. Likewise, OS at 36 and 42 months in the PP population was 91.0% (95%CI: 74.2-97.0) and 87.3% (95%CI: 69.3-95.1), respectively. Conclusion: The efficacy of nivolumab in combination with platinum-based chemotherapy in patients with resectable stage IIIA NSCLC is clearly supported by long term survival data. Keywords: NADIM trial, neoadjuvant chemo-therapy, long term survival

Published
2021

34. 418P Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Author

C. Montagut Viladot, A. Carrato Mena, A. Salud Salvia, B. Massuti Sureda, M.J. Safont Aguilera, Eduardo Díaz-Rubio, E. González-Flores, Manuel Valladares-Ayerbes, M. Granja Ortega, Cristina Canabal García, F. Rivera, Auxiliadora Gómez-España, A. Abad Esteve, P. García-Alfonso, M. Benavides, Luis Robles, E. Asensio-Martinez, E. Aranda Aguilar, V. Alonso, and Jose María Vieitez

Subjects
Oncology, medicine.medical_specialty, Pooled analysis, business.industry, Colorectal cancer, Internal medicine, Tumor resection, Medicine, Cooperative group, Hematology, business, medicine.disease
Published
2021

35. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Author

R. Lopez Castro, R. Bernabe Caro, E. Del Barco, F. Franco, J. Mosquera Martinez, B. Massuti Sureda, M.A. Sala Gonzalez, Dora Rodríguez, Joaquim Bosch-Barrera, A. Blasco Cordellat, V. Calvo, O.J. Juan Vidal, J.M. Oramas Rodriguez, Jose-Luis Gonzalez-Larriba, M. Cobo Dols, Enric Carcereny, M. Guirado, A.L. Ortega Granados, M. Provencio, and A. Estival Gonzalez

Subjects
Oncology, Transthyretin, medicine.medical_specialty, biology, business.industry, Internal medicine, medicine, biology.protein, Hematology, Lung cancer, medicine.disease, business
Published
2021

36. 455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)

Author

P. García-Alfonso, L. Cirera Nogueras, A.M. López Muñoz, Manuel Valladares-Ayerbes, E. González-Flores, M. Salgado Fernández, Rocio Garcia-Carbonero, Juan J. Cruz-Hernández, Jorge Aparicio, E. Aranda Aguilar, A. Salud Salvia, O.A. Castillo Trujillo, E. Falco Ferrer, A. Lloansi Vila, P. Pimentel Cáceres, M.A. Vicente Conesa, N Rodríguez Salas, Marta Llanos, B. Massuti Sureda, and Maria Jose Safont

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Concordance, First line, Hematology, medicine.disease, Overall response rate, Cell-free fetal DNA, Internal medicine, Cohort, medicine, Mutational status, business
Published
2021

37. 1380P Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)

Author

Franco, F., primary, Costa, E. Carcereny, additional, Rodriguez-Abreu, D., additional, Castro, R. Lopez, additional, Dols, M. Cobo, additional, Guirado, M., additional, Sureda, B. Massuti, additional, Granados, A.L. Ortega, additional, Campelo, R. Garcia, additional, Juan-Vidal, O., additional, Cordellat, A. Blasco, additional, Morillo, E. del Barco, additional, Caro, R. Bernabe, additional, Bosch-Barrera, J., additional, Gonzalez-Larriba, J.L., additional, Gonzalez, M.A. Sala, additional, Perez, J.M. Trigo, additional, Rodriguez, J.M. Oramas, additional, Estival, A., additional, and Pulla, M. Provencio, additional

Published
2020
Full Text
View/download PDF

38. 1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group

Author

Cao, M. Gonzalez, primary, Moran, T., additional, Dalmau, J., additional, Garcia-Corbacho, J., additional, Bernabe, R., additional, Vidal, O.J. Juan, additional, de Castro Carpeño, J., additional, Blanco, R., additional, Drozdowskyj, A., additional, Meyerhans, A., additional, Blanco, J., additional, Prado, J.G., additional, Clotet, B., additional, Sureda, B. Massuti, additional, Pulla, M. Provencio, additional, Molina-Vila, M.A., additional, Martinez-Picado, J., additional, and Costa, R. Rosell, additional

Published
2020
Full Text
View/download PDF

39. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Author

E. Falcó, Reyes Ferreiro-Monteagudo, T. Cano, Manuel Benavides, E. Polo, Enrique Aranda, Enrique Grande, Emma Dotor, G. Durán-Ogalla, Alfredo Carrato, Margarita Reboredo, Antonieta Salud, B. Massuti, Mercedes Rodríguez-Garrote, Jose María Vieitez, Aitana Calvo, Laura Layos, P. García Alfonso, Javier Gallego, [Carrato,A] Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Madrid, Spain. [Benavides,M, Durán-Ogalla,G] Hospital Regional Universitario Virgen de la Victoria, Málaga, Spain. [Massutí,B] Hospital General Universitario de Alicante, Alicante, Spain. [Ferreiro-Monteagudo,R, Rodriguez-Garrote,M, Grande,E] Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Alcala University, Madrid, Spain. [García Alfonso,P, Calvo,A] Hospital Gregorio Marañón, Madrid, Spain. [Falcó,E] Hospital Son Llatzer, Mallorca, Spain. [Reboredo,M] Complejo Hospitalario Universitario A Coruña, La Coruña, Spain. [Cano,T, Aranda,E] Hospital Universitario Reina Sofia, IMIBIC, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Córdoba, Spain. [Gallego,J] Hospital General Universitario de Elche, Alicante, Spain. [Viéitez,JM] Hospital Universitario Central de Asturias, Oviedo, Spain. [Layos,L] Hospital Germans Trias i Pujol, ICO, Badalona, Spain. [Salud,A] Hospital de Lleida Arnau de Vilanova, Lérida, Spain. [Polo,E] Hospital Miguel Servet, Zaragoza, Spain. [Dotor,E] Corporació Sanitària Parc Taulí, Barcelona, Spain., Financial support for this research was provided by Bayer Hispania, which has no role in the design of the study, collection, analysis, and interpretation of data, and and in writing the manuscript.

Subjects
0301 basic medicine, Male, Colorrectal cancer, Cancer Research, Persons::Persons::Age Groups::Adult::Aged::Frail Elderly [Medical Subject Headings], astenia, Colorectal cancer, Hypophosphatemia, Pyridines, health care facilities, manpower, and services, humanos, Administration, Oral, Pilot Projects, estudios de seguimiento, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], chemistry.chemical_compound, 0302 clinical medicine, Stable Disease, Elderly, Neoplasias colorrectales, Surgical oncology, Medicine, Neoplasm Metastasis, metástasis neoplásica, mediana edad, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Regorafenib, Aged, 80 and over, anciano, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Oral [Medical Subject Headings], resultado del tratamiento, proyectos piloto, First-line, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, hipofosfatemia, Progression-Free Survival, Diarrhea, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Hypertension, Female, medicine.symptom, Colorectal Neoplasms, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings], Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Phosphorus Metabolism Disorders::Hypophosphatemia [Medical Subject Headings], Research Article, Colorectal cancer, Elderly, First-line, Frail patients, Monotherapy, Regorafenib, Frail patients, medicine.medical_specialty, neoplasias colorrectales, Frail Elderly, Anciano, piridinas, Check Tags::Male [Medical Subject Headings], lcsh:RC254-282, Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertension [Medical Subject Headings], 03 medical and health sciences, Internal medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], Diseases::Neoplasms::Neoplastic Processes::Neoplasm Metastasis [Medical Subject Headings], Genetics, Humans, Adverse effect, neoplasms, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Aged, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], Dose-Response Relationship, Drug, business.industry, Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Pilot Projects [Medical Subject Headings], Phenylurea Compounds, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Monotherapy, Confidence interval, digestive system diseases, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], chemistry, Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings], Spain, Asthenia, Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenylurea Compounds [Medical Subject Headings], hipertensión, business, compuestos de fenilurea, human activities, Follow-Up Studies
Abstract

BackgroundTreatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC.MethodsFrail patients without prior advanced colorectal cancer treatment were included in the study. Definition of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or geriatric features. Main objective: to assess progression-free survival (PFS) rate at 6months. Treatment consisted of 28-daycycles of orally administered regorafenib 160mg/day (3 weeks followed by 1 week rest).ResultsForty-seven patients were included in the study. Median age was 81years (range 63-89). Frailty criteria: dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS rate at 6months was 45% (95% confidence interval [CI] 30-60]. Median PFS was 5.6months (95%CI 2.7-8.4). Median overall survival (OS) was 16months (95%CI 7.8-24). Complete response, partial response and stable disease were observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-nine patients (83%) experienced grade 3-4 adverse events (AEs). The most common grade 3-4 AEs were hypertension (15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%). There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was required in 26 patients (55%) and dose-delays in 13 patients (28%).ConclusionsThe study did not meet the pre-specified boundary of 55% PFS rate at 6months. Toxicity observed (83% patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate and overall survival results are interesting and might warrant further investigation to identify those who benefit from this approach.Trial registrationThis trial was prospectively registered at EudraCT (2013-000236-94). Date of trial registration: April 9th, 2013., Financial support for this research was provided by Bayer Hispania, which has no role in the design of the study; collection, analysis, and interpretation of data; and in writing the manuscript.

Published
2019

40. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

Author

Javier Gallego, Ferran Losa, Jose María Vieitez, E. Élez, Alfredo Carrato, Manuel Valladares-Ayerbes, B. Massuti, Maria Teresa Cano, S. Pairet, P. García-Alfonso, Jose Luis Manzano, Daniel Azuara, R. Salazar, C. Montagut, Gabriel Capellá, C. Santos Vivas, Josep Tabernero, Beatriz Bellosillo, Enrique Aranda, Joana Vidal, and R. García-Carbonero

Subjects
0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Male, Colorectal cancer, medicine.medical_treatment, DNA Mutational Analysis, Cetuximab, medicine.disease_cause, GTP Phosphohydrolases, Basal (phylogenetics), 0302 clinical medicine, Germany, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Mutation, High-Throughput Nucleotide Sequencing, Hematology, Middle Aged, anti-EGFR, ErbB Receptors, Treatment Outcome, 030220 oncology & carcinogenesis, NGS, Female, KRAS, RAS mutations, Colorectal Neoplasms, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, colorectal cancer, quadruple wild-type, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, mutant allele fraction, Growth factor receptor, Internal medicine, medicine, Humans, Allele, Protein Kinase Inhibitors, Chemotherapy, business.industry, Membrane Proteins, NGS, RAS mutations, anti-EGFR, colorectal cancer, mutant allele fraction, quadruple wild-type, medicine.disease, digestive system diseases, 030104 developmental biology, business
Abstract

Background Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is controversial. Our aim was to assess the clinical impact of detecting mutations in RAS, BRAF, PIK3CA and EGFRS492R in basal tissue tumour samples by using a highly sensitive next-generation sequencing (NGS) technology in mCRC patients treated with chemotherapy plus anti-EGFR or anti-vascular endothelial growth factor. Patients and methods Five hundred and eighty-one tumour samples from untreated mCRC patients from 7 clinical studies were collected. Mutational analysis was carried out by standard-of-care (therascreen pyro) with a sensitivity detection of 5% mutant allele fraction (MAF), and compared with NGS technology using 454GS Junior platform (Roche Applied Science, Germany) with a sensitivity of 1%. Molecular results were correlated with clinical outcomes. Results After quality assessment, 380 samples were evaluable for molecular analysis. Standard-of-care mutational analysis detected RAS, BRAFV600E or PIK3CA mutations in 56.05% of samples compared with 69.21% by NGS (P = 0.00018). NGS identified coexistence of multiple low-frequency mutant alleles in 96 of the 263 mutated cases (36.5%; range 2–7). Response rate (RR), progression-free survival (PFS) and overall survival (OS) were increasingly improved in patients with RAS wild-type, RAS/BRAF wild-type or quadruple (KRAS/NRAS/BRAF/PIK3CA) wild-type tumours treated with anti-EGFR, assessed by standard-of-care. No additional benefit in RR, PFS or OS was observed by increasing the detection threshold to 1% by NGS. An inverse correlation between the MAF of the most prevalent mutation detected by NGS and anti-EGFR response was observed (P = 0.039). EGFRS492Rmutation was not detected in untreated samples. Conclusions No improvement in the selection of patients for anti-EGFR therapy was obtained by adjusting the mutation detection threshold in tissue samples from 5% to 1% MAF. Response to anti-EGFR was significantly better in patients with quadruple wild-type tumours.

Published
2019

41. 70P Neoadjuvant chemotherapy in breast cancer in the last 2 decades: Are we improving survival? Retrospective analysis in a single institution

Author

N. Gómez, Y. Montoyo, I. Lozano, T. Martín, Álvaro Rodríguez-Lescure, M. Niveiro, Gloria Peiró, H. Ballester, B. Massuti, J. Ponce, S. Delgado, F. Aranda, Jose Javier Sanchez, L. Gomez, and D. Parra

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Breast cancer, Internal medicine, medicine, Retrospective analysis, Single institution, business
Published
2021

42. 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial

Author

M.A. Sala Gonzalez, A. Gazzah, A.L. Ortega Granados, M. Antigny, R. de las Penas Bataller, B. Massuti Sureda, Carlos Camps, Sophie Postel-Vinay, Rosa Rosell, Mariano Provencio, M.T. Moran Bueno, Benjamin Besse, David Planchard, J-C. Soria, J. Pozas Pérez, A. Lopez-Martin, M. Domine Gomez, J. Coves Sarto, Santiago Viteri, and M. Texier

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.disease, Placebo, Olaparib, chemistry.chemical_compound, chemistry, Phase (matter), Internal medicine, medicine, Platinum sensitive, Non small cell, business, Lung cancer
Published
2021

43. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

Author

Alberto Cruz-Bermúdez, Alex Martinez-Marti, J. De Castro Carpeno, M. Casarrubios, D. Rodriguez Abreu, Raquel Laza-Briviesca, Nuria Viñolas, A. Insa, I.C. Barneto Aranda, J. Casal Rubio, M. Martínez-Cutillas, Belén Sierra-Rodero, M.R. Garcia Campelo, M. Domine Gomez, M. Provencio, B. Massuti Sureda, M. Majem Tarruella, Ernest Nadal, E. Del Barco, and Y. Garitaonaindia

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Neo adjuvant, medicine.disease, Clinical trial, Stage IIIA NSCLC, Internal medicine, Medicine, business, Chemo immunotherapy, Pneumonitis
Published
2021

44. P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study)

Author

J. Mosquera, Delvys Rodriguez-Abreu, Juana Oramas, C. Gonzalez Ojea, E. Cuadrado-Albite, Thomas M. Moran, L. Gomez-Gonzalez, C. Aguado de la Rosa, M.A. Sala, B. Massuti, M. Guirado, A. Blasco, Jose Manuel Trigo, M. Cobo Dols, R. López-Castro, S. Cerezo, M. Provencio, Enric Carcereny, V. Calvo, A.L. Ortega Granados, Oscar Juan, A. Hernandez-Martinez, Alberto Ruano-Ravina, and M. Domine Gomez

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Transthyretin, biology, business.industry, Internal medicine, medicine, biology.protein, Lung cancer, medicine.disease, business
Published
2021

45. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

Author

M. Jove, J. Mosquera, R. Bernabe Caro, Alex Martinez-Marti, Delvys Rodriguez-Abreu, Alberto Cruz-Bermúdez, F. Franco, Alejandro Romero, M. Cobo Dols, Nuria Viñolas, R. Laza Briviesca, Ernest Nadal, M. Majem Tarruella, B. Massuti, A. Insa, E. Del Barco, M. Casarrubios, M. Provencio, Santiago Viteri, G. López Vivanco, J. De Castro Campeño, M. Domine Gomez, G. Huidobro, and Isidoro Barneto

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Stage IIIA NSCLC, Internal medicine, medicine, Neo adjuvant, business, Chemo immunotherapy
Published
2021

46. P52.08 Thoracic Tumors Registry (RTT): Analysis of Clinical Features and Survival in Patients with mNSCLC in Spain

Author

J. Mosquera, B. Massuti, E. Del Barco, Alejandro Padilla, M. Cobo Dols, F. Franco, Julia Calzas, S. Cerezo, Delvys Rodriguez-Abreu, R. Lopez Castro, Oscar Juan, X. Cardenas, M. Domine Gomez, A.L. Ortega Granados, Rosalia Blanco, Enric Carcereny, M. Provencio, M. Guirado, C. Garcia Benito, and F. Aparisi

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, business.industry, Internal medicine, medicine, In patient, business
Published
2021

47. 254P Different patterns of distant recurrence depending on the expression of hormone receptor in breast cancer patients with pathological complete response to neoadjuvant chemotherapy

Author

S. Delgado, Y.G. Montoyo-Pujol, M. Garcia-Escolano, F. Aranda, Gloria Peiró, I. Lozano, T. Martín, B. Massuti Sureda, H. Ballester, J. Ponce, M. Pastor-Valero, M. Reche, Álvaro Rodríguez-Lescure, and M. Niveiro

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Distant recurrence, Hematology, medicine.disease, Breast cancer, Hormone receptor, Internal medicine, Medicine, business, Pathological, Complete response
Published
2020

48. 203P Comparison of two pathologic response evaluation classification after neoadjuvant chemotherapy in patients with breast cancer

Author

M. Garcia-Escolano, Álvaro Rodríguez-Lescure, M. Niveiro, S. Delgado, F. Aranda, Y.G. Montoyo-Pujol, B. Massuti Sureda, J. Ponce, Gloria Peiró, H. Ballester, I. Lozano, and T. Martín

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Breast cancer, Internal medicine, medicine, Pathologic Response, In patient, business
Published
2020

49. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)

Author

Carlos Camps, A.L. Ortega Granados, M. Guirado, M. Provencio Pulla, E. Carcereny Costa, B. Massuti Sureda, S. Cerezo Gonzalez, J.M. Trigo Perez, Virginia Calvo, M. Cobo Dols, Delvys Rodriguez-Abreu, Thomas M. Moran, O. Juan-Vidal, J. Calzas Rodriguez, Jose-Luis Gonzalez-Larriba, E. del Barco Morillo, R. Lopez Castro, M. Domine Gomez, Joaquim Bosch-Barrera, and R. Garcia Campelo

Subjects
Oncology, medicine.medical_specialty, biology, business.industry, Hematology, Transthyretin, Internal medicine, Epidemiology, medicine, biology.protein, Non small cell, Extensive stage, business
Published
2020

50. 1380P Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study)

Author

R. Lopez Castro, E. Carcereny Costa, M.A. Sala Gonzalez, B. Massuti Sureda, Anna Estival, F. Franco, Delvys Rodriguez-Abreu, J.M. Oramas Rodriguez, Jose-Luis Gonzalez-Larriba, A.L. Ortega Granados, M. Guirado, M. Provencio Pulla, E. del Barco Morillo, Joaquim Bosch-Barrera, M. Cobo Dols, J.M. Trigo Perez, R. Garcia Campelo, A. Blasco Cordellat, R. Bernabe Caro, and O. Juan-Vidal

Subjects
Spanish population, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, In patient, Hematology, business
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results